SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
SEC Accession No. 0001213900-24-009367
Filing Date
2024-02-02
Accepted
2024-02-02 09:42:00
Documents
1
Group Members
GUY LEVYSOLEUS CAPITAL GROUP, LLCSOLEUS CAPITAL, LLC

Document Format Files

Seq Description Document Type Size
1 AMENDMENT NO. 1 TO SCHEDULE 13G ea192420-13ga1soleus_vyne.htm SC 13G/A 141674
  Complete submission text file 0001213900-24-009367.txt   143670
Mailing Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807
Business Address 685 ROUTE 202/206 N., SUITE 301 BRIDGEWATER NJ 08807 800-775-7936
VYNE Therapeutics Inc. (Subject) CIK: 0001566044 (see all company filings)

IRS No.: 453757789 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SC 13G/A | Act: 34 | File No.: 005-90268 | Film No.: 24589048
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)

Mailing Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830
Business Address 104 FIELD POINT ROAD 2ND FLOOR GREENWICH CT 06830 4752083111
Soleus Capital Master Fund, L.P. (Filed by) CIK: 0001812275 (see all company filings)

IRS No.: 981413657 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: SC 13G/A